RECENT COMMENTS

Rajesh Kumar: Is it helpfull for Overian cancer patient at advance stage? Rajesh Kumar +919681303310   »Read more

Cindy: I'm not a medical professional. My mother has been diagnosed with CUP - and was treated several year [...]   »Read more

Rajesh Kumar: +919681303310.   »Read more

Rajesh Kumar: Please write your comment here   »Read more

christian: Is gabapentin has been proposed to treat peripheric neuropathy induced by chemotherapy. At low dosa [...]   »Read more

 

Article type: Grandround

Keywords: breast screening, .

This article has 0 comments

Facebook Twitter Share - Send - Print - Pdf

 

Breast screening: a question of pros and cons not right or wrong

Breast screening:
a question of pros and cons
not right or wrong

Decades after breast screening programmes first started, their value remains hotly disputed. Some lives are saved, but it’s hard to tell how many. False-positives are a problem, but it’s a risk some are happy to take. Women need to weigh up for themselves the pros and cons of attending screening – but they can only do so if they are given clear, unbiased information.

» Marc Beishon


To read the complete article please click on the pdf icon
 
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.

ESO reserves the absolute right not to publish comments.
  Name (required)
  E-mail (will not be published) (required)
  Captcha code (required)

CancerWorld invites you to visit:

 
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.